Navigation Links
Patients at Risk for Hepatitis B Are Not Adequately Screened Before Receiving Chemotherapy Leading to the Preventable Reactivation of Hepatitis B Infection

SAN FRANCISCO, Nov. 7, 2011 /PRNewswire/ -- By examining 70,737 patients through institutional databases and medical charts, researchers at The University of Texas MD Anderson Cancer Center determined that only 20 percent of patients with newly diagnosed cancer who had hepatitis B virus (HBV) risk factors were screened for HBV infection before starting chemotherapy. This amount of screening is inadequate, according to Jessica P. Hwang, MD, MPH, the lead author of the study, "I hope my study results will increase awareness among medical providers so that they will actively screen for hepatitis B viral infection to prevent poor outcomes for these patients after their chemotherapy."

For patients with HBV infection, the danger is that their hepatitis B virus can be reactivated by chemotherapy. While those with reactivated HBV infection can be treated with antiviral therapy, initiating antiviral prophylaxis prior to chemotherapy can prevent reactivation. Using well-known HBV risk factors, a greater percentage of cancer patients with HBV infection can be accurately identified and successfully treated before starting chemotherapy.

Unfortunately, reactivation is common and may have occurred in nearly 25 percent of all patients with HBV who were newly diagnosed with cancer and received chemotherapy. This reactivation of HBV infection is preventable with screening and antiviral prophylaxis prior to the onset of chemotherapy. The study's conclusion clearly states that screening and prophylactic treatment of HBV infection prior to chemotherapy could reduce mortality in cancer patients with HBV.

"Reactivation is preventable and depends only on accurate screening and prophylaxis. For medical providers to practice effective screening, data-driven policies and strong collaboration among oncology and hepatology communities are essential," concludes Dr. Wang.

Abstract title:

Reactivation of Hepatitis B Infection Among Patients with Cancer

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in San Francisco, California, November 4 – 8, will bring together more than 8,000 researchers from 55 countries.

A press room will be available from November 5 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health of Patients with Nonalcoholic Steatohepatitis Improved Through Treatment with Anti-CD3 Antibodies
2. New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted at American College of Rheumatology Meeting
3. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
4. Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
5. Innovative Access Device Provides Hope for Select Hemodialysis Patients
6. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
7. Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
8. Hong Kong Cancer Center First in Asia to Commence Treating Cancer Patients Using TrueBeam™ System for Image-Guided Radiotherapy
9. Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
10. UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting
11. Groundbreaking Approach to Predicting Cancer Patients Response to Treatment Featured in Science Magazine
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015   Nottingham Spirk , ... announced the publication of a free whitepaper ... Medical Market". The whitepaper gives medical product companies, ... penetrating this lucrative segment. Nottingham Spirk ... to manage their own health, save money (i.e., ...
(Date:12/1/2015)... BOULDER, Colo. , Dec. 1, 2015 ... ARRY ) today announced that its Chief ... present at the Oppenheimer Annual Healthcare Conference ... to participate in the conference through a ... , --> ...
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
Breaking Medicine Technology:
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... XTC ... selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest ... CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, ...
Breaking Medicine News(10 mins):